Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here

The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences ENVB. 

The biotech company is advancing next-generation, neuroplasticity-promoting psychoactive compounds to treat depression, anxiety and addiction disorders, including those covered by the patent.

Specifically, it provides Enveric with IP rights with claims to novel compositions and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates. 

The company expects the patent to further strengthen and add value to its EVM301 compounds series, currently undergoing lead optimization and preclinical characterization. 

All these compounds -or small-molecule therapeutics- constitute New Chemical Entity (NCE) tryptamine derivatives designed to engage serotonin receptor 5HT2A and other neurotransmitters toward promoting neuroplasticity and therapeutic benefits without inducing hallucinatory effects.

Director and CEO Joseph Tucker, Ph.D. says these molecules’ “unique design” could become game-changers for depression and anxiety treatments, allowing administration of psilocybin-derived therapeutics without requiring the presence of a healthcare professional.

The company believes this, in turn, could “greatly enhance” the commercial opportunity of EVM301 series-based therapies, “benefiting patients and healthcare systems broadly by reducing the need for costly and time-intensive requirements for supervision throughout the treatment.” 

All New Chemical Entities (NCEs) have been created through Enveric’s discovery and development platform, “The Psybrary,” including the lead program of next-generation synthetic psilocin prodrugs, the EVM201 series, and its lead drug candidate EB-373 targeting psychiatric disorders.

Into the cannabis industry? Then our imminent Cannabis Capital Conference is where you ought to be! Whether to close your deals or just get acquainted with the sector’s best, come join us on Sept. 27-28 in Chicago for our 17th edition. Tickets HERE.

Photo: Benzinga edit with photo by Bacsica, aiyoshi597, Gisele Yashar and Gorodenkoff on Shutterstock.